Skip Navigation

Adalvo offers an extensive portfolio of arthritis medications

17 November 2022

We at Adalvo continue to strengthen our comprehensive arthritis medication portfolio, covering a unique selection for this indication.

Arthritis is the swelling and tenderness of one or more joints. The main symptoms of arthritis are joint pain and stiffness, which typically worsen with age. The most common types of arthritis are osteoarthritis and rheumatoid arthritis.

Adalvo is focusing its attention on this segment, to satisfy the growing patient need for such products. In this respect, we are offering an extensive list of products indicated in the treatment of several types arthritis:

According to Precedence Research, the global rheumatoid arthritis drugs market size is estimated to surpass around $70 billion by 2030 and growing at a CAGR of 1.72% from 2022 to 2030. The global rheumatoid arthritis drugs market size was estimated at $60 billion in 2021.

At Adalvo, our purpose is to make a real difference to patients around the world and to deliver a diversified and competitive portfolio and support our partners in every step of their journey.